In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 60 days of free consultation

 

Efficacy and safety of carvedilol and losartan with various combinations of bronchodilators in patients with chronic heart failure due to coronary artery disease combined with COPD

Session Poster Session 4

Speaker Vladimir Evdokimov

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session
  • FP Number : P2056

Authors : V Evdokimov (Moscow,RU), A Evdokimova (Moscow,RU), E Kovalenko (Moscow,RU), E Yushchuk (Moscow,RU)

15 views

Authors:
V Evdokimov1 , A Evdokimova1 , E Kovalenko1 , E Yushchuk1 , 1State University of Medicine & Dentistry - Moscow - Russian Federation ,

Citation:

Purpose: to compare clinical efficacy and safety of carvedilol and losartan with various combinations of bronchodilators in complex therapy in patient with CHF due to CAD combined with COPD.
Methods: after enrollment in this trial 98 patients (70 men and 28 women), aged 64.1 ± 4.8 years, with CHF classes II to III (New York Heart Association) combined with moderate to severe COPD (GOLD-2015) with initial ejection fraction of the left ventricle (LVEF) less than 45%, were randomized into three groups – tiotropium (18 µg daily, n=36), indacaterol (150 µg daily, n=32) and tiotropium/indacaterol group (18/150 µg daily, n=30). Patients of all groups received the complex CHF treatment comprising carvedilol, losartan, diuretics, nitrates, cardiac glycosides (if necessary) and basic COPD therapy (inhalation corticosteroids). Echocardiography, exercise tolerance, 24-hour electrocardiography, respiratory function test were assessed at baseline and after 6 months of treatment. The quality of life was evaluated by MYHFQ, SGRQ and mMRC.
Results: after 6 months of therapy the improvement of clinical condition and quality of life were marked in all groups. In 1st, 2nd and 3rd group LVEF was increased by 20.9%, 18.3% and 22.5%, pulmonary hypertension decreased by 21.2%, 22.8% and 26.7%, episodes of silent myocardial ischemia decreased by 52.3%, 47.6% and 52.4%, respectively. Towards the end of the observation period, in all groups there was a confident and authentic increase of FEV1 witch made 10.4%, 7.8%, and 11.9% accordingly. Patients showed statistically significant and clinically meaningful reduction of SGRQ, MYHFQ scores and MMRC dyspnea grade (see table 1). All treatment regimens were well tolerated. 
Conclusions: the carvedilol and losartan with tiotropium and/or indacaterol administration in patients with CHF combined with COPD raises efficiency of treatment, improves quality of life, basic parameters of central hemodinamics and pulmonary function. Efficacy of long-acting inhaled anticholinergic agent (tiotropium) and long-acting ß-agonist (indacaterol) in patient with CHF due to CAD combined with COPD are similar. Combination of these drugs significantly enhances the positive effects of the therapy.

Group 1

tiotropium

(n=36)

Group 2

indacaterol

(n=32)

Group 3

tiotropium

+indacaterol

(n=30)

CHF class (NYHA)

-17,2*

-16,1*

-20,1*

mMRC

-20,1*

-23,2*

-27,5*

6 minute walk test

+18,2*

+21,4*

+24,4**

MLHFQ

-27*

-25*

-30,2*

SGRQ

-symptoms

-activities

-impact

-15,4*

-12,8*

-22,5*

-9,2

-18,6*

-10,6

-21,4*

-8,3

-24,4*

-14,1*

-26,4**

-13,7*

* - p<0,05, ** - p<0,01 compared to baseline


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are